AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25956891 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets for 90 days (n = 47)
Number of subjects: 87
Study 23254903 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate (1500 mg/day)
Number of subjects: 8
Study 23254903 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 21281410 — intervention group
Group type: EXPERIMENTAL
Intervention: Online LSVT®
Number of subjects: 34
Study 21281410 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face LSVT®
Number of subjects: 34
Study 19195731 — intervention group
Group type: EXPERIMENTAL
Intervention: Field matching techniques (including half beam blocking and machine rotations)
Number of subjects: 0
Study 19195731 — intervention group
Group type: EXPERIMENTAL
Intervention: Geometric alignment techniques
Number of subjects: 0
Study 19195731 — intervention group
Group type: EXPERIMENTAL
Intervention: Film dosimetry with a breast-shaped phantom
Number of subjects: 0
Study 19195731 — intervention group
Group type: COMPARATOR
Intervention: Gap techniques
Number of subjects: 0
Study 16703969 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic thoracic medial branch blocks
Number of subjects: 55
Study 15867730 — intervention group
Group type: EXPERIMENTAL
Intervention: Indwelling urethral catheters removed at midnight
Number of subjects: 8
Study 15867730 — intervention group
Group type: COMPARATOR
Intervention: Indwelling urethral catheters removed in the morning
Number of subjects: 8
Study 12134989 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifocal IOL
Number of subjects: 40
Study 12134989 — intervention group
Group type: COMPARATOR
Intervention: Monofocal IOL
Number of subjects: 40
Study 9607277 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual energy X-ray absorptiometry for evaluating bone density in patients with proximal femur fractures.
Number of subjects: 369
Study 9607277 — intervention group
Group type: EXPERIMENTAL
Intervention: Threshold values for ZYA established for different areas of the proximal femur: femoral neck -1.3 SD, Ward's triangle -1.5 SD, trochanteric area -0.4 SD.
Number of subjects: 369
Study 7706096 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 hours of bedrest after sheath removal
Number of subjects: 85
Study 7706096 — intervention group
Group type: COMPARATOR
Intervention: 8 hours of bedrest after sheath removal
Number of subjects: 85
Study 2705602 — intervention group
Group type: EXPERIMENTAL
Intervention: Free care
Number of subjects: 100
Study 2705602 — intervention group
Group type: COMPARATOR
Intervention: Cost-sharing plans
Number of subjects: 100
Study 335789 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine (CPZ) 200 mg per day
Number of subjects: 0
Study 335789 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine (CPZ) 400 mg per day
Number of subjects: 0
Study 335789 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine (CPZ) 600 mg per day
Number of subjects: 0
Study 335789 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine (CPZ)
Number of subjects: 0
Study 31441769 — intervention group
Group type: EXPERIMENTAL
Intervention: Home gardens intervention (details on dosage and duration not available)
Number of subjects: 176
Study 31441769 — intervention group
Group type: COMPARATOR
Intervention: Baseline measures collected before the intervention
Number of subjects: 176
Study 28553836 — intervention group
Group type: EXPERIMENTAL
Intervention: Riluzole (100 mg/day)
Number of subjects: 104
Study 28553836 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 26363409 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmodium falciparum sporozoites (CPS) immunization
Number of subjects: 15
Study 23474315 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG
Number of subjects: 345
Study 20870464 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional TENS
Number of subjects: 23
Study 20870464 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture-like TENS
Number of subjects: 23
Study 19786417 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert tutor group
Number of subjects: 30
Study 19786417 — intervention group
Group type: COMPARATOR
Intervention: Non-expert tutor group
Number of subjects: 30
Study 17303257 — intervention group
Group type: EXPERIMENTAL
Intervention: Early decompression (transnasal trans‐sphenoidal optic nerve decompression)
Number of subjects: 31
Study 15025850 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrine + raubasine
Number of subjects: 74
Study 15025850 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 10706231 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily vitamin‐mineral supplementation at 50% of the U.S. recommended daily allowance (RDA) for 4 months
Number of subjects: 468
Study 10706231 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 468
Study 8951686 — intervention group
Group type: EXPERIMENTAL
Intervention: Cysteamine drops (0.5% and 1.0%) administered preoperatively every half hour for two, four, six or eight hours
Number of subjects: 0
Study 8951686 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 1348805 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection treatment (1‐2 ml of 1 in 10,000 adrenaline injected at four to six sites around the ulcer)
Number of subjects: 93
Study 1348805 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment alone (control)
Number of subjects: 93
Study 1348805 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection treatment
Number of subjects: 93
Study 3908121 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 20-40 mg twice daily
Number of subjects: 25
Study 3908121 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol 200-400 mg twice daily
Number of subjects: 25
Study 3908121 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine and Labetalol in combination
Number of subjects: 25
Study 3908121 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol alone
Number of subjects: 25
Study 3908121 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine alone
Number of subjects: 25
Study 3908121 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Nifedipine and Labetalol)
Number of subjects: 25
Study 3908121 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol alone and in combination with Nifedipine
Number of subjects: 25
Study 3908121 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine and Labetalol
Number of subjects: 25
Study 30704452 — intervention group
Group type: EXPERIMENTAL
Intervention: Students who wrote questions for General Pathology (Immunopathology)
Number of subjects: 184
Study 30704452 — intervention group
Group type: EXPERIMENTAL
Intervention: Students who wrote questions for Pathophysiology (Respiratory system)
Number of subjects: 184
Study 30704452 — intervention group
Group type: EXPERIMENTAL
Intervention: Male students writing good questions in Pathophysiology
Number of subjects: 184
Study 28928100 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-alfentanil (Group A)
Number of subjects: 150
Study 28928100 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-fentanyl (Group F)
Number of subjects: 150
Study 28928100 — intervention group
Group type: COMPARATOR
Intervention: Propofol only (Group P)
Number of subjects: 150
Study 25990225 — intervention group
Group type: EXPERIMENTAL
Intervention: Towards Flourishing Mental Health Promotion Strategy
Number of subjects: 13
Study 25990225 — intervention group
Group type: COMPARATOR
Intervention: Existing public health home visiting program
Number of subjects: 13
Study 23848077 — intervention group
Group type: EXPERIMENTAL
Intervention: Novasource Diabet Smartflex
Number of subjects: 15
Study 22143221 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based health education intervention (12 weeks duration)
Number of subjects: 49
Study 22143221 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 49
Study 19853687 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of oral anticoagulation therapy and clopidogrel 75 mg/d
Number of subjects: 496
Study 19853687 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy (clopidogrel + oral anticoagulants + aspirin)
Number of subjects: 496
Study 16500914 — intervention group
Group type: EXPERIMENTAL
Intervention: 5FU/LV/oxaliplatin
Number of subjects: 302
Study 16500914 — intervention group
Group type: COMPARATOR
Intervention: 5FU/LV
Number of subjects: 302
Study 15601473 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visits by experienced home nurses (at least 8 visits over 18 months)
Number of subjects: 330
Study 15601473 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 330
Study 15601473 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visits by experienced home nurses
Number of subjects: 330
Study 11482539 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy
Number of subjects: 135
Study 11482539 — intervention group
Group type: COMPARATOR
Intervention: Prescription of multivitamins
Number of subjects: 135
Study 9284853 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human interleukin-10 (1.0, 2.5, 5.0, 10, 25, or 50 micrograms/kg)
Number of subjects: 54
Study 9284853 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 8227938 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyedrops to eyes that were closed
Number of subjects: 38
Study 8227938 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyedrops to eyes that were open
Number of subjects: 38
Study 8227938 — intervention group
Group type: EXPERIMENTAL
Intervention: Spray to eyes that were closed
Number of subjects: 38
Study 8227938 — intervention group
Group type: EXPERIMENTAL
Intervention: Spray to eyes that were open
Number of subjects: 38
Study 3468302 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 S IgG
Number of subjects: 0
Study 3468302 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3291634 — intervention group
Group type: EXPERIMENTAL
Intervention: Impregnated sheets with benzyl benzoate
Number of subjects: 36
Study 3291634 — intervention group
Group type: COMPARATOR
Intervention: Placebo sheets (inactive sheets)
Number of subjects: 36
Study 31928523 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis (24 sessions over 6 months)
Number of subjects: 40
Study 31928523 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care (Control group)
Number of subjects: 40
Study 29463233 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cholera vaccine (OCV)
Number of subjects: 0
Study 29463233 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27852348 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy (DBT)
Number of subjects: 109
Study 27852348 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy plus (CBT+)
Number of subjects: 109
Study 27852348 — intervention group
Group type: COMPARATOR
Intervention: Guided Self-Help Cognitive Behavior Therapy (cGSH)
Number of subjects: 109
Study 27852348 — intervention group
Group type: EXPERIMENTAL
Intervention: DBT
Number of subjects: 109
Study 27852348 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT
Number of subjects: 109
Study 26365791 — intervention group
Group type: EXPERIMENTAL
Intervention: IUD insertion with baseline dysmenorrhea scores
Number of subjects: 199
Study 26365791 — intervention group
Group type: EXPERIMENTAL
Intervention: IUD insertion with insertion pain
Number of subjects: 199
Study 26365791 — intervention group
Group type: EXPERIMENTAL
Intervention: IUD insertion
Number of subjects: 199
Study 23201301 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooking intervention with professional chefs
Number of subjects: 4
Study 23201301 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 4
Study 21973111 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced treatment group
Number of subjects: 33
Study 21973111 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus group participation
Number of subjects: 33
Study 18514485 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Number of subjects: 0
Study 18514485 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 0
Study 18514485 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 0
Study 16556244 — intervention group
Group type: EXPERIMENTAL
Intervention: Headache response at 0.5 hours
Number of subjects: 0
Study 12930465 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse‐Family Partnership pilot study home visitation program
Number of subjects: 225
Study 12930465 — intervention group
Group type: COMPARATOR
Intervention: Traditional Public Health Field Nursing (PHFN) services
Number of subjects: 225
Study 10955773 — intervention group
Group type: EXPERIMENTAL
Intervention: 4‐HPR (200 mg once daily)
Number of subjects: 82
Study 10955773 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 10955773 — intervention group
Group type: EXPERIMENTAL
Intervention: 4‐HPR
Number of subjects: 82
Study 8694306 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil small dose (0.5 micrograms.kg‐1.min‐1)
Number of subjects: 161
Study 8694306 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil large dose (1 microgram.kg‐1.min‐1)
Number of subjects: 161
Study 1349488 — intervention group
Group type: EXPERIMENTAL
Intervention: terfenadine 60 mg
Number of subjects: 12
Study 1349488 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 3934932 — intervention group
Group type: EXPERIMENTAL
Intervention: iohexol
Number of subjects: 60
Study 3934932 — intervention group
Group type: COMPARATOR
Intervention: metrizamide
Number of subjects: 60
Study 31947735 — intervention group
Group type: EXPERIMENTAL
Intervention: PLAYTOD program
Number of subjects: 0
Study 29948199 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluntary contractions combined with hypopressive exercises (HYPO)
Number of subjects: 24
Study 29948199 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback exercises combined with transvaginal electrical stimulations (ELEC)
Number of subjects: 24
Study 27026424 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioimpedance spectroscopy (BIS) by Xitron 4200
Number of subjects: 70
Study 27026424 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-electrode multifrequency impedance (MFBIA) by Tanita MC180MA
Number of subjects: 70
Study 27026424 — intervention group
Group type: COMPARATOR
Intervention: Dual energy X-ray absorptiometry (DXA)
Number of subjects: 70
Study 27026424 — intervention group
Group type: COMPARATOR
Intervention: Doubly labeled water (DLW)
Number of subjects: 70
Study 25281929 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo (lidocaine)
Number of subjects: 18
Study 25281929 — intervention group
Group type: COMPARATOR
Intervention: Nocebo (capsaicin)
Number of subjects: 18
Study 21664014 — intervention group
Group type: EXPERIMENTAL
Intervention: VR/Haptics IV Simulator (IV sim)
Number of subjects: 114
Study 21664014 — intervention group
Group type: COMPARATOR
Intervention: Conventional arm model (IV arm)
Number of subjects: 114
Study 21664014 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IV arm and IV sim
Number of subjects: 114
Study 21095484 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic atorvastatin 20 mg/d
Number of subjects: 244
Study 21095484 — intervention group
Group type: COMPARATOR
Intervention: Branded atorvastatin 20 mg/d
Number of subjects: 244
Study 18664782 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 32
Study 18664782 — intervention group
Group type: COMPARATOR
Intervention: Enoximone
Number of subjects: 32
Study 15997937 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontal ligament injection with the Wand
Number of subjects: 25
Study 15997937 — intervention group
Group type: COMPARATOR
Intervention: Traditional syringe injection
Number of subjects: 25
Study 15997937 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference of technique
Number of subjects: 25
Study 11797017 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary dipsticks (Multistix 8‐SG) analyzed by the reflectance spectrophotometric method (Clinitek 50)
Number of subjects: 144
Study 11797017 — intervention group
Group type: COMPARATOR
Intervention: Quantitative urine culture (QUC)
Number of subjects: 144
Study 11797017 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary dipsticks (UD) strategy
Number of subjects: 144
Study 9549398 — intervention group
Group type: EXPERIMENTAL
Intervention: Rest/postnitroglycerin (0.4 mg sublingually) technetium‐99m tetrofosmin SPET
Number of subjects: 28
Study 9549398 — intervention group
Group type: COMPARATOR
Intervention: Thallium‐201 rest/redistribution SPET
Number of subjects: 28
Study 9549398 — intervention group
Group type: COMPARATOR
Intervention: Thallium‐201 rest/reinjection SPET
Number of subjects: 28
Study 8019029 — intervention group
Group type: EXPERIMENTAL
Intervention: University of Wisconsin (UW) solution
Number of subjects: 149
Study 8019029 — intervention group
Group type: COMPARATOR
Intervention: Hypothermic continuous pulsatile perfusion
Number of subjects: 149
Study 2783734 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D2 supplementation (400 IU/day)
Number of subjects: 46
Study 2783734 — intervention group
Group type: COMPARATOR
Intervention: Placebo (unsupplemented human milk)
Number of subjects: 46
Study 2783734 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard infant formula
Number of subjects: 46
Study 30803542 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% NaOCl irrigation (1.5 N)
Number of subjects: 94
Study 30803542 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% NaOCl irrigation (2.5 N)
Number of subjects: 94
Study 30803542 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 N + intermittent canal brushing with Navitip FX (NFX)
Number of subjects: 94
Study 30803542 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 N + intermittent XP-endo Finisher (XPF)
Number of subjects: 94
Study 30803542 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 N + circumferential filing (CF)
Number of subjects: 94
Study 30803542 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 N + 1-min Self-adjusting File (SAF)
Number of subjects: 94
Study 30803542 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 N + mechanical instrumentation using #90–110 files (MI)
Number of subjects: 94
Study 30803542 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 N + intermittent passive ultrasonic irrigation (PUI)
Number of subjects: 94
Study 30803542 — intervention group
Group type: COMPARATOR
Intervention: Initial (no intervention)
Number of subjects: 94
Study 29158593 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical intervention for CLP (three different surgical strategies)
Number of subjects: 429
Study 28323586 — intervention group
Group type: EXPERIMENTAL
Intervention: Home cervical traction
Number of subjects: 21
Study 28323586 — intervention group
Group type: COMPARATOR
Intervention: Control (no traction)
Number of subjects: 21
Study 24338514 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine eye test administered to children with BHS
Number of subjects: 30
Study 24338514 — intervention group
Group type: COMPARATOR
Intervention: Control group of healthy children
Number of subjects: 30
Study 22008384 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 60
Study 22008384 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 60
Study 19615915 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% bolus (20 ml) before rib spreading (pre-RS)
Number of subjects: 60
Study 19615915 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% bolus (20 ml) after rib spreading (post-RS)
Number of subjects: 60
Study 19615915 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior thoracotomy (AT)
Number of subjects: 60
Study 19615915 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterolateral thoracotomy (PT)
Number of subjects: 60
Study 19615915 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-RS (AT)
Number of subjects: 60
Study 19615915 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-RS (AT)
Number of subjects: 60
Study 19615915 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-RS (PT)
Number of subjects: 60
Study 19615915 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-RS (PT)
Number of subjects: 60
Study 19615915 — intervention group
Group type: EXPERIMENTAL
Intervention: Need for meperidine as a rescue drug
Number of subjects: 60
Study 17518923 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromotor task training (NTT), 9 weekly sessions of 30 minutes each
Number of subjects: 26
Study 17518923 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention for at least 9 weeks)
Number of subjects: 26
Study 15370633 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoridated milk (250 mL, 5 ppm F)
Number of subjects: 20
Study 15370633 — intervention group
Group type: COMPARATOR
Intervention: Non-fluoridated milk
Number of subjects: 20
Study 11842840 — intervention group
Group type: EXPERIMENTAL
Intervention: Thick palatal appliance
Number of subjects: 18
Study 11842840 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication
Number of subjects: 18
Study 11842840 — intervention group
Group type: COMPARATOR
Intervention: No-treatment group
Number of subjects: 18
Study 9704737 — intervention group
Group type: COMPARATOR
Intervention: Intermediate-dose methotrexate (IDMTX) with leucovorin rescue (regimen A)
Number of subjects: 727
Study 9704737 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen A plus asparaginase (ASP) (regimen B)
Number of subjects: 727
Study 9704737 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen A plus a 24-hour infusion of cytarabine (AraC) (regimen C)
Number of subjects: 727
Study 7983238 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release codeine (SRC) 150 mg every 12 hours for 5 doses
Number of subjects: 13
Study 7983238 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release codeine phosphate (IRC) 60 mg (2 x 30 mg) every 4 hours for the first 3 doses, and 30 mg every 4 hours thereafter for 12 doses
Number of subjects: 13
Study 7983238 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release codeine (SRC)
Number of subjects: 13
Study 7983238 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release codeine phosphate (IRC)
Number of subjects: 13